Compare Ascendis Pharma A/S (ASND) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vital Farms Inc — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while Vital Farms Inc trades at $13.2 (market cap $554.89M). The key difference: Ascendis Pharma A/S is far larger — about 32× Vital Farms Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| ASND | VITL | |
|---|---|---|
Market Cap | $17.74B | $554.89M |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $52.41 |
52-Week Low | $163.32 | $8.28 |
Enterprise Value | $18.11B | $557.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Vital Farms (VITL) trades at $12.95, down 0.08% on the day, with a bullish technical signal supported by moving averages but overbought RSI readings. The stock shows solid profitability with a 6.1% net margin and 15.44% ROE, though earnings missed expectations in two recent quarters. Valuation appears reasonable with a P/E of 12.45 and P/S of 0.75. Recent news highlights volatility, including a class-action lawsuit filed in May 2026, while cash flow trends indicate significant investing outflows.
The outlook is mixed: analyst consensus leans bullish with a $13.50 price target, but risks include legal overhangs, earnings volatility, and negative cash flow. Revenue growth is modest, projected at $784M for 2026, but profit margins are declining. Investors should weigh strong fundamentals against near-term headwinds from litigation and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
